NASDAQ:CASI CASI Pharmaceuticals (CASI) Stock Forecast, Price & News $2.42 -0.15 (-5.84%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$2.40▼$2.5750-Day Range$2.05▼$3.7052-Week Range$1.45▼$4.86Volume27,555 shsAverage Volume32,280 shsMarket Capitalization$32.23 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability CASI Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside313.2% Upside$10.00 Price TargetShort InterestHealthy3.57% of Float Sold ShortDividend StrengthN/ASustainability-1.50Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.88) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector280th out of 987 stocksBiological Products, Except Diagnostic Industry40th out of 156 stocks 3.5 Analyst's Opinion Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, CASI Pharmaceuticals has a forecasted upside of 313.2% from its current price of $2.42.Amount of Analyst CoverageCASI Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.57% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in CASI Pharmaceuticals has recently decreased by 0.74%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCASI Pharmaceuticals has received a 62.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Melphalan" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CASI Pharmaceuticals is -1.50. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for CASI Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CASI on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.62% of the stock of CASI Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CASI Pharmaceuticals are expected to grow in the coming year, from ($1.88) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CASI Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CASI Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CASI Pharmaceuticals (NASDAQ:CASI) StockCASI Pharmaceuticals, Inc. engages in developing and commercializing therapeutics and pharmaceutical products. The company was founded in 1991 and is headquartered in Beijing, China.Read More Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CASI Stock News HeadlinesJune 7, 2023 | americanbankingnews.comStockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI)May 30, 2023 | americanbankingnews.comCASI Pharmaceuticals (NASDAQ:CASI) Receives New Coverage from Analysts at StockNews.comJune 10, 2023 | Vector Vest (Ad)Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 28, 2023 | finance.yahoo.comWe Think CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth CarefullyMay 24, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Raised by AnalystMay 18, 2023 | americanbankingnews.comShort Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Drops By 5.0%May 17, 2023 | finanznachrichten.deCASI Pharmaceuticals, Inc. Announces First Quarter 2023 Financial ResultsMay 17, 2023 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTSJune 10, 2023 | Vector Vest (Ad)Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 15, 2023 | americanbankingnews.comCASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.comMay 4, 2023 | americanbankingnews.comShort Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Grows By 6.5%May 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Cytosorbents (CTSO)April 28, 2023 | americanbankingnews.comCASI Pharmaceuticals (NASDAQ:CASI) Now Covered by Analysts at StockNews.comApril 26, 2023 | msn.comCASI Pharmaceuticals GAAP EPS of -$3.01 misses by $2.64, revenue of $43.12M beats by $32.31MApril 26, 2023 | finance.yahoo.comCASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022April 26, 2023 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSApril 17, 2023 | finance.yahoo.comImproved Revenues Required Before CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock's 114% Jump Looks JustifiedApril 12, 2023 | benzinga.comWill CASI Pharmaceuticals Inc (CASI) Outperform the Rest of the Stocks in the Healthcare Sector?April 4, 2023 | americanbankingnews.comShort Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Drops By 6.0%March 26, 2023 | americanbankingnews.comCASI Pharmaceuticals (CASI) Scheduled to Post Quarterly Earnings on MondayMarch 23, 2023 | marketwatch.comLisinopril Market Top Players and Forecast till 2031March 22, 2023 | finanznachrichten.deCASI Pharmaceuticals, Inc. Completes Redomiciliation MergerMarch 17, 2023 | marketwatch.comHypoxia Inducible Factor 1 Alpha Inhibitor Market Size 2023 Research Report by Growth Rate Analysis and Forecast till 2027March 13, 2023 | marketwatch.comTumor Necrosis Factor Inhibitors Market Size 2023 - 2030: About its Application, Qrganization Size, Sales Volume, and Regional OutlookMarch 9, 2023 | msn.comFoghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue EstimatesFebruary 14, 2023 | markets.businessinsider.comBTIG Reaffirms Their Hold Rating on MEI Pharma (MEIP)February 6, 2023 | finance.yahoo.comA CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 16% last yearSee More Headlines CASI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CASI Company Calendar Last Earnings11/12/2021Today6/10/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CASI CUSIPN/A CIK895051 Webwww.casipharmaceuticals.com Phone861065086063Fax301-315-2437Employees176Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+313.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,010,000.00 Net Margins-90.65% Pretax Margin-82.20% Return on Equity-72.23% Return on Assets-35.63% Debt Debt-to-Equity RatioN/A Current Ratio4.74 Quick Ratio4.13 Sales & Book Value Annual Sales$43.11 million Price / Sales0.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book0.74Miscellaneous Outstanding Shares13,320,000Free Float10,492,000Market Cap$32.23 million OptionableNot Optionable BetaN/A Key ExecutivesWei-Wu HeChairman & Chief Executive OfficerWei ZhangPresident & Chief Financial OfficerChun Hua WangChief Operation OfficerAlexander A. ZukiwskiChief Medical Officer & Executive Vice PresidentFu Qiang ZhangChief Commercial OfficerKey CompetitorsPluriNASDAQ:PLUROKYO PharmaNASDAQ:OKYOEvaxion Biotech A/SNASDAQ:EVAXAziyo BiologicsNASDAQ:AZYOCoeptis TherapeuticsNASDAQ:COEPView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPSold 19,069 shares on 5/16/2023Ownership: 0.288%Wellington Shields Capital Management LLCBought 180,143 shares on 5/11/2023Ownership: 1.352%Wellington Shields & Co. LLCBought 139,315 shares on 5/11/2023Ownership: 1.046%James HuangBought 33,300 shares on 9/8/2022Total: $142,524.00 ($4.28/share)James HuangBought 19,162 shares on 9/6/2022Total: $74,540.18 ($3.89/share)View All Insider TransactionsView All Institutional Transactions CASI Stock - Frequently Asked Questions Should I buy or sell CASI Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI shares. View CASI analyst ratings or view top-rated stocks. What is CASI Pharmaceuticals' stock price forecast for 2023? 2 brokers have issued 12 month price targets for CASI Pharmaceuticals' shares. Their CASI share price forecasts range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 313.2% from the stock's current price. View analysts price targets for CASI or view top-rated stocks among Wall Street analysts. How have CASI shares performed in 2023? CASI Pharmaceuticals' stock was trading at $1.79 on January 1st, 2023. Since then, CASI shares have increased by 35.2% and is now trading at $2.42. View the best growth stocks for 2023 here. When is CASI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our CASI earnings forecast. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its quarterly earnings data on Friday, November, 12th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.10. The biotechnology company earned $8.11 million during the quarter, compared to analyst estimates of $7.77 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 72.23% and a negative net margin of 90.65%. During the same quarter in the previous year, the business earned ($1.40) EPS. When did CASI Pharmaceuticals' stock split? CASI Pharmaceuticals's stock reverse split on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM). What is CASI Pharmaceuticals' stock symbol? CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI." Who are CASI Pharmaceuticals' major shareholders? CASI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Shields Capital Management LLC (1.35%), Wellington Shields & Co. LLC (1.05%) and Susquehanna International Group LLP (0.29%). Insiders that own company stock include James Huang, Larry Zhang, Weihao Xu and Wei-Wu He. View institutional ownership trends. How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CASI Pharmaceuticals' stock price today? One share of CASI stock can currently be purchased for approximately $2.42. How much money does CASI Pharmaceuticals make? CASI Pharmaceuticals (NASDAQ:CASI) has a market capitalization of $32.23 million and generates $43.11 million in revenue each year. The biotechnology company earns $-41,010,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis. How many employees does CASI Pharmaceuticals have? The company employs 176 workers across the globe. How can I contact CASI Pharmaceuticals? CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The official website for the company is www.casipharmaceuticals.com. The biotechnology company can be reached via phone at 861065086063, via email at ir@casipharmaceuticals.com, or via fax at 301-315-2437. This page (NASDAQ:CASI) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.